Follicular Lymphoma - Treatment and Prognostic Factors

Overview

Journal Rev Bras Hematol Hemoter

Publisher Elsevier

Specialty Hematology

Date 2012 Oct 11

PMID 23049385

Citations 18

Authors

Stefano Luminari

Monica Bellei

Irene Biasoli

Massimo Federico

Affiliations

Soon will be listed here.

Abstract

Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.

Citing Articles

Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.

Jimenez C, Garrote-de-Barros A, Lopez-Portugues C, Hernandez-Sanchez M, Diez P Int J Mol Sci. 2024; 25(9).

PMID: 38731863 PMC: 11083628. DOI: 10.3390/ijms25094644.

Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.

Suponin A, Zhelnov P, Potanin A, Chekalov A, Lomazov A, Vladimirova K Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543058 PMC: 10974604. DOI: 10.3390/ph17030272.

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.

Bellone M, Pradelli L, Molica S, De Francesco A, Ghislieri D, Guardalben E Clinicoecon Outcomes Res. 2021; 13:661-671.

PMID: 34321898 PMC: 8313400. DOI: 10.2147/CEOR.S317885.

Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature.

Peeters M, Geusens J, Van der Cruyssen F, Michaux L, de Leval L, Tousseyn T Pathol Oncol Res. 2021; 27:642433.

PMID: 34257608 PMC: 8262163. DOI: 10.3389/pore.2021.642433.

Function of Deptor and its roles in hematological malignancies.

Morales-Martinez M, Lichtenstein A, Vega M Aging (Albany NY). 2021; 13(1):1528-1564.

PMID: 33412518 PMC: 7834987. DOI: 10.18632/aging.202462.

References

Rohatiner A, Gregory W, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A . Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol. 2005; 23(10):2215-23. DOI: 10.1200/JCO.2005.06.146. View

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-62. DOI: 10.1200/JCO.2008.21.3991. View

Rohatiner A, Nadler L, Davies A, Apostolidis J, Neuberg D, Matthews J . Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25(18):2554-9. DOI: 10.1200/JCO.2006.09.8327. View

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26(32):5156-64. DOI: 10.1200/JCO.2008.17.2015. View

Witzig T, Gordon L, Cabanillas F, Czuczman M, Emmanouilides C, Joyce R . Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20(10):2453-63. DOI: 10.1200/JCO.2002.11.076. View

Luminari S, Cox M, Montanini A, Federico M . Prognostic tools in follicular lymphomas. Expert Rev Hematol. 2010; 2(5):549-62. DOI: 10.1586/ehm.09.34. View

Witzig T, Flinn I, Gordon L, Emmanouilides C, Czuczman M, Saleh M . Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20(15):3262-9. DOI: 10.1200/JCO.2002.11.017. View

Federico M, Vitolo U, Zinzani P, Chisesi T, Clo V, Bellesi G . Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood. 2000; 95(3):783-9. View

Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A . Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall.... Blood. 2008; 111(8):4004-13. DOI: 10.1182/blood-2007-10-116749. View

10.

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R . Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP.... Blood. 2005; 106(12):3725-32. DOI: 10.1182/blood-2005-01-0016. View

11.

Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P . Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3):1110-7. DOI: 10.1200/JCO.1997.15.3.1110. View

12.

van Oers M, Klasa R, Marcus R, Wolf M, Kimby E, Gascoyne R . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108(10):3295-301. DOI: 10.1182/blood-2006-05-021113. View

13.

Montoto S, Canals C, Rohatiner A, Taghipour G, Sureda A, Schmitz N . Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007; 21(11):2324-31. DOI: 10.1038/sj.leu.2404850. View

14.

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View

15.

Advani R, Rosenberg S, Horning S . Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004; 22(8):1454-9. DOI: 10.1200/JCO.2004.10.086. View

16.

Pugh T, Ballonoff A, Newman F, Rabinovitch R . Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2010; 116(16):3843-51. DOI: 10.1002/cncr.25149. View

17.

Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi J . Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008; 112(13):4824-31. DOI: 10.1182/blood-2008-04-153189. View

18.

Young R, Longo D, Glatstein E, Ihde D, Jaffe E, Devita Jr V . The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988; 25(2 Suppl 2):11-6. View

19.

Ardeshna K, Smith P, Norton A, Hancock B, Hoskin P, MacLennan K . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003; 362(9383):516-22. DOI: 10.1016/s0140-6736(03)14110-4. View

20.

Salles G, Seymour J, Offner F, Lopez-Guillermo A, Belada D, Xerri L . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2010; 377(9759):42-51. DOI: 10.1016/S0140-6736(10)62175-7. View